Element Biosciences
Focus: Element Biosciences develops genetic analysis and sequencing tools for precision medicine and rare disease research. The company is Series C+ backed and positioned in the competitive genomics instrumentation market.
Profile data last refreshed 17m ago · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
16
Should You Work at Element Biosciences?
AI assessmentStrong fit for instrumentation/sequencing engineers and customer-facing roles seeking growth-stage equity upside; risky for traditional drug development career paths.
Why Work Here
- Recent Samsung investment (June 2026) signals major capital infusion and validates the company's multiomics platform as a credible Illumina challenger.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
11 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Jewel Patch Wearable Cardioverter Defibrillator
Sudden Cardiac ArrestClinical Trials (1)
NCT05201495The Jewel IDE Study
N/AHelp build intelligence for Element Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.